Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Abstract Background Sunitinib and pazopanib are extensively used as first-line treatment of metastatic renal cell carcinoma (mRCC). We performed this meta-analysis to assess the anti-tumor effectiveness, toxicity, and total costs of the two drugs among patients with mRCC/advanced RCC (aRCC). Materia...

Full description

Bibliographic Details
Main Authors: Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, Wenxiong Zhang
Format: Article
Published: BMC 2019-05-01
Series:BMC Cancer
Online Access: